Biodelivery Story

All StoriesRisk
Raphi Shpitalnik Story
<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>BS</div>
BDSI -- USA Stock  

USD 3.30  0.04  1.20%

Macroaxis News
By Raphi Shpitalnik  
Macroaxis Story
Lets try to concentrate on the odds of Biodelivery Sci to fully recover from the current drop as its shares went up 2.50%. This firm current daily volatility is 2.92 percent, with a beta of 1.34 and an alpha of -0.01 over DOW. While some baby boomers are getting worried about pharmaceutical products, it is reasonable to concentrate on Biodelivery Sci Intl. We will analyze why Biodelivery Sci investors may still consider a stake in the business.
Published over a month ago
View all stories for Biodelivery Sci | View All Stories
Is Biodelivery Sci (NASDAQ:BDSI) a good short term trade as volatility boosts?
Biodelivery Sci Intl currently holds roughly 100.18 M in cash with 30.89 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99.
We provide trade advice to complement the prevailing expert consensus on Biodelivery Sci Intl. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Investing in Biodelivery Sci, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Biodelivery Sci along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Biodelivery Sci's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Biodelivery Sci in the context of predictive analytics.
Hype
Prediction
Details
Intrinsic
Valuation
Details
7 Analysts
Consensus
Details
Earnings
Estimates (5)
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Biodelivery Sci. Your research has to be compared to or analyzed against Biodelivery Sci's peers to derive any actionable benefits. When done correctly, Biodelivery Sci's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Biodelivery Sci Intl.

How important is Biodelivery Sci's Liquidity

Biodelivery Sci financial leverage refers to using borrowed capital as a funding source to finance Biodelivery Sci Intl ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biodelivery Sci financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biodelivery Sci's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Biodelivery Sci, but it might be worth checking our own buy vs. sell analysis

Biodelivery Sci Correlation with Peers

Investors in Biodelivery can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Biodelivery Sci Intl. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Biodelivery Sci and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Biodelivery is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Biodelivery for more details

Exercise or conversion by Scott Plesha of 20834 shares of Biodelivery Sci subject to Rule 16b-3

Legal trades by Biodelivery Sci insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biodelivery insider trading alert for exercise of restricted stock units by Scott Plesha, the corporate stakeholder, on 16th of March 2021. This event was filed by Biodelivery Sciences Inte with SEC on 2021-03-16. Statement of changes in beneficial ownership - SEC Form 4. Scott Plesha currently serves as senior vice president - sales and marketing of Biodelivery Sci Intl [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another Deeper Perspective

Biodelivery Sci Intl secures Sharpe Ratio (or Efficiency) of -0.0253, which signifies that the company had -0.0253% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Biodelivery Sci Intl exposes twenty-seven different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Biodelivery Sci Intl Risk Adjusted Performance of 0.0401, downside deviation of 2.78, and Mean Deviation of 2.32 to double-check the risk estimate we provide.
EQ
DRNA
EDIT
DTIL
EARS
EQ
0.7-0.260.650.61
EQ
DRNA
0.7-0.590.490.55
DRNA
EDIT
-0.26-0.59-0.11-0.5
EDIT
DTIL
0.650.49-0.110.41
DTIL
EARS
0.610.55-0.50.41
EARS
EQ
DRNA
EDIT
DTIL
EARS
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Are Biodelivery Sci technical ratios showing a correction?

Current Treynor Ratio is up to 0.08. Price may drop again. Biodelivery Sci Intl currently demonstrates below-average downside deviation. It has Information Ratio of 0.01 and Jensen Alpha of -0.01. However, we advise investors to further question Biodelivery Sci Intl expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biodelivery Sci's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biodelivery Sci's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Biodelivery Sci

While some other firms in the biotechnology industry are either recovering or due for a correction, Biodelivery Sci may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Biodelivery as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biodelivery Sci.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Biodelivery Sci Intl. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
Macroaxis Wealth Optimization Platform
 
Feedback Blog
Made with optimal in San Francisco
2021 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY